ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1658

Interferon Related Soluble Mediator Concentrations Significantly Correlate with Disease Activity in SLE Patients with Active Interferon Pathways

Rufei Lu1, Cristina Arriens2, Teresa Aberle3, Stan Kamp3, Melissa E. Munroe3, Tim Gross1, Wade DeJager3, Susan Macwana3, Virginia C. Roberts3, Stephen Apel4, Hua Chen3, Eliza Chakravarty5, Katherine Thanou3, Joan T. Merrill6 and Judith A. James7, 1Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Oklahoma Medical Research Foundation, Oklahoma City, OK, 5Oklahoma Medical research af, Edmond, OK, 6Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 7Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: cytokines and interferons, Gene Expression, SLE

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 6, 2017

Session Title: Systemic Lupus Erythematosus – Human Etiology and Pathogenesis Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose : Interferon (IFN) pathways are dysregulated in a subset of patients with systemic lupus erythematosus (SLE). IFN dysregulation likely contributes to SLE pathogenesis and influences the disease course. This study examined correlations between IFN transcriptional modular scores, biologically relevant soluble mediators, and SLE disease activity in patients with or without the IFN signature.

Methods : Adult SLE patients (n=49) meeting >/= 4 ACR classification criteria provided longitudinal samples at times of low (SLEDAI<6) and high (SLEDAI≥6) disease activity. Immune pathway activity was evaluated by modular transcriptional analysis of Illumina Beadchip Microarray gene expression data in 98 patient samples and 20 age, race and gender matched healthy controls. Plasma soluble mediators (n=23) and antinuclear antibodies (n=11) were assessed by multiplex-bead based assays and ELISAs. Non-parametric paired tests were used for intra-individual univariate analyses, conditional logistic regression for multivariate analyses.

Results : Within a given individual, IFN signatures remained active and did not change with disease activity. In patients with active IFN signatures (n=29), several soluble mediators were elevated during high compared to low disease activity. These included MIG (median 168 pg/mL vs. 100 pg/mL; p<0.01), IFNa (5.82 pg/mL vs. 3.69 pg/mL; p<0.01), MCP1 (240 pg/mL vs. 209 pg/mL; p<0.01), BLyS (1.88 ng/mL vs. 1.18 ng/mL, p<0.01), TNFRI (2.82 ng/mL vs. 1.98 ng/mL, p<0.05) and TNFRII (622 pg/mL vs. 552 pg/mL, p<0.01). Additionally, patients with active IFN signatures showed higher M4.11 plasma cell module scores and dsDNA concentrations during high vs. low disease activity (p<0.05). Periods of high disease activity in patients with active IFN signatures were best distinguished by M4.11 plasma cell module scores, BLyS, MIG and hemoglobin in multivariate logistic modeling (p<0.01).     

Conclusion: Although IFN activity correlates with disease severity in lupus populations, IFN module scores may not correlate significantly with intra-individual changes in disease activity. In contrast, plasma concentrations of IFN- and TNF-related soluble mediators significantly correlated with SLEDAI scores, suggesting that longitudinal monitoring of soluble mediators may be useful in individuals at increased risk of disease flares. 

 


Disclosure: R. Lu, None; C. Arriens, Exagen, 2; T. Aberle, None; S. Kamp, None; M. E. Munroe, None; T. Gross, None; W. DeJager, None; S. Macwana, None; V. C. Roberts, None; S. Apel, None; H. Chen, None; E. Chakravarty, None; K. Thanou, None; J. T. Merrill, Anthera Pharmaceuticals, Lilly, EMD Serono, GlaxoSmithKline and Biogen., 5; J. A. James, None.

To cite this abstract in AMA style:

Lu R, Arriens C, Aberle T, Kamp S, Munroe ME, Gross T, DeJager W, Macwana S, Roberts VC, Apel S, Chen H, Chakravarty E, Thanou K, Merrill JT, James JA. Interferon Related Soluble Mediator Concentrations Significantly Correlate with Disease Activity in SLE Patients with Active Interferon Pathways [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/interferon-related-soluble-mediator-concentrations-significantly-correlate-with-disease-activity-in-sle-patients-with-active-interferon-pathways/. Accessed January 31, 2023.
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/interferon-related-soluble-mediator-concentrations-significantly-correlate-with-disease-activity-in-sle-patients-with-active-interferon-pathways/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences